What is the recommended dosing and safety information for Orzeyful (orexin‑enhancing medication) in adults with narcolepsy type 1?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Orzeyful (Oveporexton) for Narcolepsy Type 1: Dosing and Safety

Orzeyful (oveporexton) is dosed at 2 mg followed by 5 mg daily (taken 3 hours apart) or 2 mg twice daily for adults with narcolepsy type 1, representing the first FDA-approved orexin receptor 2 agonist that directly addresses the underlying orexin deficiency in NT1. 1, 2

Recommended Dosing Regimens

Based on the pivotal phase 2 trial, the most effective dosing strategies are:

  • 2 mg twice daily (dosed 3 hours apart): Demonstrated mean improvement of 23.5 minutes on Maintenance of Wakefulness Test and -13.8 point reduction in Epworth Sleepiness Scale 1
  • 2 mg followed by 5 mg daily (dosed 3 hours apart): Showed mean improvement of 25.4 minutes on MWT and -12.8 point reduction in ESS 1
  • Alternative regimen: 7 mg once daily also showed efficacy (15.0 minute MWT improvement, -11.3 ESS reduction) 1

The 2 mg twice daily and 2 mg/5 mg regimens are preferred as they also significantly reduced cataplexy frequency (weekly incidence of 3.14 and 2.48 episodes respectively vs 8.76 for placebo at week 8). 1

Critical Safety Information

Common Adverse Events (Expect These)

  • Insomnia (48% of patients): Most cases resolve within 1 week of continued treatment 1
  • Urinary urgency (33%) and urinary frequency (32%) 1
  • Pollakiuria (55%) in related OX2R agonist trials 3
  • Salivary hypersecretion (25%) 3
  • Headache, blurred vision, hyperhidrosis 1, 3

Important Clinical Considerations

Pregnancy and Breastfeeding: Based on animal data, oveporexton may cause fetal harm. Human data are insufficient to determine risk. 1 This is a critical counseling point for women of childbearing age.

No hepatotoxicity observed: Unlike some other wake-promoting agents, oveporexton did not demonstrate hepatotoxic effects in clinical trials. 1

Controlled substance status: While oveporexton is not mentioned as a scheduled substance in available data (unlike modafinil which is Schedule IV), clinicians should verify current DEA scheduling.

Clinical Context and Treatment Algorithm

When to Use Oveporexton

Oveporexton should be considered as a first-line option for NT1 because it:

  1. Addresses the underlying orexin deficiency rather than just symptoms 4, 2
  2. Improves all core NT1 symptoms: excessive daytime sleepiness, cataplexy, and cognitive dysfunction 1, 5
  3. Demonstrates cognitive benefits including improved attention (PVT lapses), memory (CPAL errors), and executive function (ONB, IDSST-s) 5

Comparison to Guideline-Recommended Alternatives

The 2021 AASM guidelines provide STRONG recommendations for four medications in NT1 6:

  • Modafinil
  • Pitolisant (another orexin-enhancing agent, but a histamine H3 receptor inverse agonist)
  • Sodium oxybate (FDA black box warning for CNS depression and respiratory depression; Schedule III controlled substance) 6
  • Solriamfetol (Schedule IV controlled substance) 6

Oveporexton's advantage: It is the only approved therapy directly replacing deficient orexin signaling via selective OX2R agonism, potentially offering superior disease-modifying effects compared to symptomatic treatments. 4, 2

Practical Management Approach

Initiation Strategy

  1. Start with 2 mg twice daily (3 hours apart) or 2 mg/5 mg daily regimen
  2. Counsel patients about transient insomnia - emphasize that 48% experience this but most cases resolve within 1 week 1
  3. Warn about urinary symptoms - urgency and frequency affect approximately one-third of patients 1

Monitoring

  • Week 1-2: Contact patient to assess insomnia tolerance and urinary symptoms
  • Week 6-8: Assess efficacy using objective measures (MWT if available) or ESS scores
  • Ongoing: Monitor for sustained cataplexy reduction and cognitive improvements 1, 5

Common Pitfalls to Avoid

  • Don't discontinue prematurely for insomnia - most cases self-resolve within 1 week
  • Don't overlook pregnancy planning - counsel women of childbearing age about potential fetal harm
  • Don't expect immediate cataplexy control - significant reduction occurs by week 8 1

Evidence Quality Assessment

The approval is based on high-quality phase 2 data 1 with phase 3 trials completed and additional global studies ongoing. 2 The 8-week phase 2 trial demonstrated clinically meaningful improvements across all primary and secondary endpoints with adjusted p-values ≤0.001 for wakefulness measures. 1 Long-term efficacy and safety data beyond 8 weeks remain limited and require further evaluation. 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.